MicroMass recruits three strategy vets

Share this article:
MicroMass Communications has added three new VP, senior strategists to better address the marketing shift from mass-market communications to a more patient-focused approach.

Account planning veteran Mark Klapper joins the Cary, NC-based relationship marketing agency from Unit 7, where he led planners, analysts and psychologists as EVP, director of planning and consulting services.

Kim Levy, a 17-year pharma marketing veteran of both the corporate and agency sides, joins MicroMass to develop strategy on the agency's oncology accounts. Prior to joining MicroMass, Levy was at Adair-Greene Healthcare Communications.

Rick Mazzetti joins MicroMass with over 20 years of pharma industry experience including marketing, sales management and alliance management positions at GlaxoSmithKline, Quintiles Transnational, and LipoScience. His previous brand management experience lies in the areas of central nervous system, cardiology, women's health, men's health, dermatology, and antibiotics.
President Jay Bigelow said in a statement that these new hires come as the agency addresses the ongoing industry shift away from investing in direct-to-consumer advertising.

“With increased pressure to cut back on direct-to-consumer advertising, we are finding that more and more brands are looking for alternate strategies to communicate with patients and professionals, such as relationship marketing and disease awareness campaigns,” Bigelow said. “Enhanced by these new hires, our strategic services group… [will] help clients navigate through this change.”

Share this article:

Email Newsletters

More in News

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.

Shire, AbbVie join forces for $55B

Shire, AbbVie join forces for $55B

The deal includes a $1.6-billion fee if AbbVie tries to walk away.

Next target for hep. C drugmakers: co-infections

Next target for hep. C drugmakers: co-infections

An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.